Myelodysplastic syndromes, chronic myeloproliferative diseases, ative diseases

被引:14
作者
Vardiman, JW [1 ]
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL USA
关键词
myelodysplastic syndromes; MDS; chronic myeloproliferative diseases; myelodysplastic/myeloproliferative diseases; chronic myelomonocytic leukemia;
D O I
10.1016/S0740-2570(03)00025-X
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This article reviews the major diagnostic criteria for the myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases. Perhaps the most important message this article intends to convey is that the proper diagnosis and classification of myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases requires a multidisciplinary approach that correlates morphologic findings with clinical, genetic, and other laboratory information. Thus, the pathologist is central to the diagnosis of these disorders. Not only do pathologists have the morphologic skills to interpret peripheral blood and bone marrow aspirate smears and bone marrow biopsy specimens properly, but they often are responsible for interpretation of flow-cytometry and molecular genetic data as well. Pathologists are therefore in the best position to determine whether all the individual pieces of data fit together for the diagnosis under consideration. An additional important theme in the paper is that "well-prepared" blood and bone marrow aspirate smears and "adequate, well-processsed" bone marrow biopsy specimens are essential for the diagnosis. In the author's opinion, inadequate specimens usually account for most of the difficulties encountered in the proper diagnosis of these diseases. It is hoped that when an excellent specimen is available, the guidelines contained in this article may provide the pathologist with assistance in arriving at the most appropriate diagnosis. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:154 / 179
页数:26
相关论文
共 161 条
[21]  
Brunning RD., 2001, World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, P63
[22]   OCCURRENCE, ETIOLOGY, AND CLINICAL-SIGNIFICANCE OF EXTREME THROMBOCYTOSIS - A STUDY OF 280 CASES [J].
BUSS, DH ;
CASHELL, AW ;
OCONNOR, ML ;
RICHARDS, F ;
CASE, LD .
AMERICAN JOURNAL OF MEDICINE, 1994, 96 (03) :247-254
[23]  
CERVANTES F, 1991, ACTA HAEMATOL-BASEL, V85, P124
[24]   F-blast is a useful marker for differentiating hypocellular refractory anemia from aplastic anemia [J].
Choi, JW ;
Fujino, M ;
Ito, M .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 75 (03) :257-260
[25]   APOPTOSIS IS A COMMON HISTOPATHOLOGICAL FINDING IN MYELODYSPLASIA - THE CORRELATE OF INEFFECTIVE HEMATOPOIESIS [J].
CLARK, DM ;
LAMPERT, IA .
LEUKEMIA & LYMPHOMA, 1990, 2 (06) :415-418
[26]  
COGSWELL PC, 1989, BLOOD, V74, P2629
[27]   HISTOPATHOLOGY OF MYELODYSPLASTIC SYNDROMES - THE FAB CLASSIFICATION (PROPOSALS) APPLIED TO BONE-MARROW BIOPSY [J].
DELACRETAZ, F ;
SCHMIDT, PM ;
PIGUET, D ;
BACHMANN, F ;
COSTA, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1987, 87 (02) :180-186
[28]   The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes [J].
Deliliers, GL ;
Annaloro, C ;
Soligo, D ;
Oriani, A .
LEUKEMIA & LYMPHOMA, 1998, 28 (3-4) :231-+
[29]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[30]  
Dupriez B, 1996, BLOOD, V88, P1013